Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 1;155(6):679-687.
doi: 10.1001/jamadermatol.2019.0069.

Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma

Laura Calomarde-Rees  1 , Rosario García-Calatayud  2 , Celia Requena Caballero  1 , Esperanza Manrique-Silva  1 , Víctor Traves  3 , Zaida García-Casado  4 , Virtudes Soriano  5 , Rajiv Kumar  6 , Eduardo Nagore  1   2
Affiliations

Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma

Laura Calomarde-Rees et al. JAMA Dermatol. .

Abstract

Importance: The lymphatic and the hematogenous pathways have been proposed for disease progression in cutaneous melanoma, but association with recurrence has not been studied separately to date.

Objective: To identify the risk factors associated with lymphatic and hematogenous metastasis.

Design, setting, and participants: This retrospective cohort study included 1177 patients with malignant melanoma treated at Instituto Valenciano de Oncología, València, Spain. Data were retrieved from the melanoma database from January 1, 2000, through December 31, 2015, and analyzed from June 1 to 30, 2018.

Exposure: Malignant melanoma at stages I to II.

Main outcomes and measures: Analyses of survival free of lymphatic and hematogenous metastasis were performed using Kaplan-Meier curves and Cox proportional hazards regression.

Results: For the 1177 patients included in the study analysis (51.1% women; median age at diagnosis, 55 years [interquartile range, 42-68 years), median follow-up was 75 months (interquartile range, 33-121 months); 108 (9.2%) developed lymphatic metastasis, and 108 (9.2%) developed hematogenous metastasis. In the multivariate analysis, being older than 55 years (hazard ratio [HR], 1.9; 95% CI, 1.2-3.1), tumor in the head/neck (HR, 1.7; 95% CI, 1.0-2.9) and acral locations (HR, 2.4; 95% CI, 1.3-4.5), greater Breslow thickness (HR for >4.00 mm, 5.4; 95% CI, 2.4-12.4), and presence of vascular invasion (HR, 3.2; 95% CI, 0.9-10.6) were associated with lymphatic spreading. Hematogenous metastasis was associated with greater Breslow thickness (HR for >4.00 mm, 10.4; 95% CI, 3.6-29.7), the absence of regression (HR, 0.1; 95% CI, 0.0-1.0), TERT promoter mutations (HR, 2.9; 95% CI, 1.5-5.7), and BRAF mutations (HR, 1.9; 95% CI, 1.1-3.6).

Conclusions and relevance: Risk factors associated with lymphatic and hematogenous metastasis differ. Follow-up and adjuvant treatment strategies may therefore need to be adapted to individual clinical, histopathologic, and molecular characteristics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Kaplan-Meier Curves for Lymphatic Disease–Free Survival
Includes the variables that were significant in the multivariate study.
Figure 2.
Figure 2.. Kaplan-Meier Curves for Hematogenous Disease–Free Survival
Includes the variables that were significant in the multivariate study.
See this image and copyright information in PMC

Comment in

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi:10.3322/caac.21166 - DOI - PubMed
    1. Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, et al. . Skin cancer incidence and mortality in Spain: a systematic review and meta-analysis. Actas Dermosifiliogr. 2016;107(4):318-328. doi:10.1016/j.ad.2015.12.008 - DOI - PubMed
    1. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012;29(7):699-706. doi:10.1007/s10585-012-9503-3 - DOI - PMC - PubMed
    1. Morton DL, Thompson JF, Cochran AJ, et al. ; MSLT Group . Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599-609. doi:10.1056/NEJMoa1310460 - DOI - PMC - PubMed
    1. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151(2):298-307. doi:10.1111/j.1365-2133.2004.06132.x - DOI - PubMed